umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Pooled cohort study on height and risk of cancer and cancer death
Umeå universitet, Medicinska fakulteten, Institutionen för kirurgisk och perioperativ vetenskap, Urologi och andrologi.
Umeå universitet, Medicinska fakulteten, Institutionen för kirurgisk och perioperativ vetenskap, Urologi och andrologi.
Visa övriga samt affilieringar
2014 (Engelska)Ingår i: Cancer Causes and Control, ISSN 0957-5243, E-ISSN 1573-7225, Vol. 25, nr 2, s. 151-159Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

PURPOSE: To assess the association between height and risk of cancer and cancer death.

METHODS: The metabolic syndrome and cancer project is a prospective pooled cohort study of 585,928 participants from seven cohorts in Austria, Norway, and Sweden. Hazard ratios (HRs) and 95 % confidence intervals (CIs) for cancer incidence and death were estimated in height categories and per 5-cm increment for each cancer site using Cox proportional hazards model.

RESULTS: During a mean follow-up of 12.7 years (SD = 7.2), 38,862 participants were diagnosed with cancer and 13,547 participants died of cancer. Increased height (per 5-cm increment) was associated with an increased overall cancer risk in women, HR 1.07 (95 % CI 1.06-1.09), and in men, HR 1.04 (95 % CI 1.03-1.06). The highest HR was seen for malignant melanoma in women, HR 1.17 (95 % CI 1.11-1.24), and in men HR 1.12 (95 % CI 1.08-1.19). Height was also associated with increased risk of cancer death in women, HR 1.03 (95 % CI 1.01-1.16), and in men, HR 1.03 (95 % CI 1.01-1.05). The highest HR was observed for breast cancer death in postmenopausal women (>60 years), HR 1.10 (95 % CI 1.00-1.21), and death from renal cell carcinoma in men, HR 1.18 (95 % CI 1.07-1.30). All these associations were independent of body mass index.

CONCLUSION: Height was associated with risk of cancer and cancer death indicating that factors related to height such as hormonal and genetic factors stimulate both cancer development and progression.

Ort, förlag, år, upplaga, sidor
Springer Berlin/Heidelberg, 2014. Vol. 25, nr 2, s. 151-159
Nyckelord [en]
Body stature, Body height, Epidemiology, Cancer risk, Cohort study
Nationell ämneskategori
Cancer och onkologi Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi Biomedicinsk laboratorievetenskap/teknologi
Identifikatorer
URN: urn:nbn:se:umu:diva-82646DOI: 10.1007/s10552-013-0317-7ISI: 000330848600002PubMedID: 24173535OAI: oai:DiVA.org:umu-82646DiVA, id: diva2:662085
Tillgänglig från: 2013-11-06 Skapad: 2013-11-06 Senast uppdaterad: 2018-06-08Bibliografiskt granskad
Ingår i avhandling
1. Prospective studies of hormonal and life-style related factors and risk of cancer
Öppna denna publikation i ny flik eller fönster >>Prospective studies of hormonal and life-style related factors and risk of cancer
2014 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Abstract [en]

Background: Androgens are important in prostate cancer development but how circulating levels of androgens affect risk of prostate cancer of different aggressiveness is not clear. Being childless has been associated with a lower risk of prostate cancer, but it is not clear if this association is causal or a result of residual confounding. Fathering of dizygotic twins, a marker of high fertility, has not been studied in relation to risk of prostate cancer.

Another marker of life-long hormonal exposure is height, which has been associated with increased risk of cancer and cancer death. However, the association to separate cancer sites has not been consistent.

The aims of this thesis were to study hormonal factors (paper I), and proxies of hormonal factors (paper II and III), and risk of prostate cancer; as well as height and risk of cancer and cancer death by separate sites (paper IV).

Methods: Study designs were i) case-control studies, nested within the Västerbotten Intervention Project (paper I), and in Prostate Cancer database Sweden 2.0 (PCBaSe 2.0) (paper II and III), and ii) cohort study, in the Metabolic Syndrome and Cancer project (Me-Can) (paper IV).

Results, prostate cancer: In paper I, increasing levels of serum androgens were not associated with risk of prostate cancer overall or in tumor risk categories. In paper II, childless men had a lower risk of prostate cancer, overall and in all risk categories, compared to fathers, an association which was in part explained by differences in marital status and educational level.  In paper III, fathers of dizygotic twins did not have an increased risk of prostate cancer, either overall or in risk categories, when compared to fathers of singletons.

Results, cancer overall: In paper IV, height was associated with an increased risk of cancer and cancer death overall in both women and men. The strongest association for cancer was to malignant melanoma in both women and men, and for cancer death to post-menopausal breast cancer in women and renal cell carcinoma in men.

Conclusions: These studies indicate that hormonal factors, when studied as serum levels or when studied using proxies of fertility, do not have a major impact on the risk of prostate cancer. The association between height and an increased risk of cancer appears robust for total cancer and cancer death, as well as for several separate cancer sites.

Ort, förlag, år, upplaga, sidor
Umeå: Umeå Universitet, 2014. s. 76
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 1648
Nyckelord
prostate cancer, epidemiology, androgens, risk factors, fatherhood status, dizygotic twins, height, cohort, case-control, prospective
Nationell ämneskategori
Urologi och njurmedicin Cancer och onkologi
Forskningsämne
cancerepidemiologi
Identifikatorer
urn:nbn:se:umu:diva-88308 (URN)978-91-7601-029-7 (ISBN)
Disputation
2014-06-05, Bergasalen, Umeå Universitetssjukhus, byggnad 27, Umeå, 09:00 (Svenska)
Opponent
Handledare
Forskningsfinansiär
Cancerfonden, 11 0471Vetenskapsrådet, 825-2010-5950
Tillgänglig från: 2014-05-07 Skapad: 2014-04-30 Senast uppdaterad: 2018-06-07Bibliografiskt granskad

Open Access i DiVA

fulltext(517 kB)522 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 517 kBChecksumma SHA-512
4f16a65b2c278e0103cb5fd74f69550eda13ce01f811f801612196a015e997c9745544086cefdbbd6a30113fd1d971a091b76083f87e94ce1a5c1ef490d16730
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Wirén, SaraHäggström, ChristelHallmans, GöranJonsson, HåkanStocks, TanjaStattin, Pär

Sök vidare i DiVA

Av författaren/redaktören
Wirén, SaraHäggström, ChristelHallmans, GöranJonsson, HåkanStocks, TanjaStattin, Pär
Av organisationen
Urologi och andrologiNäringsforskningEnheten för biobanksforskningOnkologi
I samma tidskrift
Cancer Causes and Control
Cancer och onkologiFolkhälsovetenskap, global hälsa, socialmedicin och epidemiologiBiomedicinsk laboratorievetenskap/teknologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 522 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 491 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf